ScholarLens Back to search
2002•Yiyao daobaoRequires access

A Cost-effect Analysis of Cefepime and Ceftazidime in the Treatment of Respiratory Tract Infections

Tan Xian

Open publisher page 0 citations

Abstract

Objective:To compare the economic benefits of cefepime and ceftazidime in the treatment of lower respiratory tract infections. Methods:68 patients with lower respiratory tract infections were randomly divided into group A and group B. 36 patients of group A were treated with cefepime, while 32 patients of group B received ceftazidime treatment. The economic benefits were evaluated by a pharmacoeconomic cost effect analysis. Results:The cost effect of cefepime (cure rate: 146.55±49.29; efficacy rate: 64.66±21.75)was lower than that of ceftazidime (cure rate: 164.38±54.97; efficacy rate: 67.60±22.74) in the treatment of lower respiratory tract infections. Conclusion:Cefepime is superior to ceftazidime in the treatment of lower respiratory tract infections as appraised by the cost effect.

About this research paper

What this paper is about

Objective:To compare the economic benefits of cefepime and ceftazidime in the treatment of lower respiratory tract infections. Methods:68 patients with lower respiratory tract infections were randomly divided into group A and group B. 36 patients of group A were treated with cefepime, while 32 patients of group B received ceftazidime treatment. The economic benefits were evaluated by a pharmacoeconomic cost effect analysis. Results:The cost effect of cefepime (cure rate: 146.55±49.29; efficacy rate: 64.66±21.75)was lower than that of ceftazidime (cure rate: 164.38±54.97; efficacy rate: 67.60±22.74) in the treatment of lower respiratory tract infections. Conclusion:Cefepime is superior to ceftazidime in the treatment of lower respiratory tract infections as appraised by the cost effect.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objective:To compare the economic benefits of cefepime and ceftazidime in the treatment of lower respiratory tract infections. Methods:68 patients with lower respiratory tract infections were randomly divided into group A and group B. 36 patients of group A were treated with cefepime, while 32 patients of group B received ceftazidime treatment. The economic benefits were evaluated by a pharmacoeconomic cost effect analysis. Results:The cost effect of cefepime (cure rate: 146.55±49.29; efficacy rate: 64.66±21.75)was lower than that of ceftazidime (cure rate: 164.38±54.97; efficacy rate: 67.60±22.74) in the treatment of lower respiratory tract infections. Conclusion:Cefepime is superior to ceftazidime in the treatment of lower respiratory tract infections as appraised by the cost effect.

Key concepts: Cefepime, Ceftazidime, Medicine, Respiratory tract infections, Respiratory tract, Pharmacoeconomics, Internal medicine, Intensive care medicine

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
A Cost-effect Analysis of Cefepime and Ceftazidime in the Treatment of Respiratory Tract Infections — Research Paper | ScholarLens